Inhibikase Therapeutics (IKT) Q3 2026: EPS Beat Driven by a Larger Share Count
As seen on the 24/7 Wall St. homepage on November 10, 2026.
The $193.3 million cash position funds operations through the Part B topline readout, with an interim Part A safety look due in the first half of 2027. R&D nearly doubled to $15.0 million as the Phase 3 IMPROVE-PAH trial scaled to 79 activated sites across 28 countries, and a bigger share count, not spending restraint, drove the smaller-than-expected per-share loss.
Continue ReadingShow less
Inhibikase Therapeutics reported a GAAP loss per share of $0.10 for the third quarter of 2026, exceeding the Wall Street consensus of $0.125 by 20%. The improvement in the per-share figure came from a higher weighted-average share count absorbing the loss across a larger denominator, while the net loss itself deepened to $20.47 million from $11.93 million a year ago.
The widening net loss was driven almost entirely by research and development spending, which nearly doubled to $15.0 million from $7.6 million a year earlier as the Phase 3 IMPROVE-PAH trial for IKT-001 expanded aggressively. The company now has 79 clinical sites activated across 28 countries, working toward a planned total of 180 sites. SG&A expenses also rose, to $7.2 million from $5.6 million.
The $50 million equity raise completed with RA Capital Management in July 2026 left Inhibikase with $193.3 million in cash and securities at quarter end. Management says that balance is sufficient to fund operations through the Part B topline readout, though that projection assumes full and timely exercise of the outstanding Series A and B Warrants, which introduces some conditionality to the runway.
Sponsored
The next concrete milestone on the calendar is an interim safety readout from Part A of IMPROVE-PAH, covering approximately 50 patients, expected in the first half of 2027. Nonclinical data from combination studies pairing IKT-001 with sotatercept are also expected to begin arriving in Q1 2027, and regulatory filings to support combination therapy within Part B are already underway. Results from Group 2 and Group 3 pulmonary hypertension studies are expected during 2027 and in late 2027 or early 2028, respectively.
IKT-001 carries FDA Orphan Drug Designation, granted in July 2026, which brings potential benefits including tax credits, user fee exemptions, and up to seven years of market exclusivity if approved. The company has no revenue and remains entirely dependent on a single asset, meaning the Part A interim safety look in the first half of 2027 will be the most closely watched near-term signal for investors.
Mentioned: IKT